腾讯网1 个月
AECOPD 患者出院后为何首选 LAMA+LABA，什么情况下加 ICS？
（2）支气管舒张剂是慢阻肺的基础治疗药物，若无禁忌证，推荐选择 LABA + LAMA 联合治疗。 （3）ICS 的合理使用：在本次急性加重期间系统性和（或）雾化糖皮质激素使用前外周血 EOS ≥ 150 个/μL，或伴哮喘样特征者，出院时优先选择 LABA + LAMA + ICS。 注：a EOS < 100 ...
Nature6 年
Therapies for COPD
LABA and LAMA are used to relieve the symptoms of bronchoconstriction ... is the only LAMA available in the market. Seretide/Advair (fluticasone propionate + salmeterol; GlaxoSmithKline) and ...
pharmaphorum9 年
Boehringer's Spiolto tops Seretide in head-to-head COPD trial
Boehringer Ingelheim's recently-approved Spiolto is more effective than GlaxoSmithKline's Seretide/Advair in improving ... antagonist (LAMA) and long-acting beta agonist (LABA) is more effective ...
pharmaphorum9 天
Novartis’ COPD combo show benefits in switching from established drugs
Novartis' Ultibro Breezhaler is one of a new generation of treatments competing to take over from standard treatments such as GSK’s Advair ... therapy (LABA+ICS * or LABA or LAMA) experienced ...